Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus OZOBAX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus OZOBAX DS.
DANTRIUM vs OZOBAX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant